Since then, it has been widely recognized that constitutive activation of JAK‐STAT signaling plays a pivotal role in the pathogenesis of MPN with or without the presence of the JAK2 V617F mutation. The gene discussed is JAK2; the disease is myeloproliferative neoplasm.